What is inaccurate regarding genetic testing in underwriting?

In underwriting, it is common practice that the costs associated with genetic testing are typically borne by the insurer or a designated third party, rather than the proposed insured. This facilitates access to necessary information that can influence underwriting decisions without placing a financial burden on the individual seeking insurance. By covering these costs, insurers can ensure a more extensive understanding of the potential risks involved, which can lead to more accurate premium pricing and risk assessment.

Understanding the context and implications of the other statements helps to further clarify why the correct answer revolves around the financial responsibility for testing costs. Informed consent is indeed a crucial step in the process, ensuring that individuals are fully aware of what the testing entails and how the results will be used. Additionally, sharing test results with the insured’s physician is often permitted, as it helps in providing comprehensive care, maintaining the individual's health priorities. Lastly, the aim of avoiding discrimination is a foundational principle in the context of genetic testing, aligning with ethical and legal standards that protect individuals from bias based on their genetic information.